{"id":5766,"date":"2011-08-25T11:31:36","date_gmt":"2011-08-25T15:31:36","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=5766"},"modified":"2011-08-25T11:31:36","modified_gmt":"2011-08-25T15:31:36","slug":"cambridge-u-k-spin-off-gains-9-5-million-in-early-funding","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=5766","title":{"rendered":"Cambridge U.K. Spin-Off Gains $9.5 Million in Early Funding"},"content":{"rendered":"<p><a href=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/08\/CurrencyDice_M4DGROUP_Flickr.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignright size-full wp-image-5768\" title=\"Currency Dice\" src=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/08\/CurrencyDice_M4DGROUP_Flickr.jpg\" alt=\"Currency dice (MD4 Group\/Flickr)\" width=\"300\" height=\"200\" srcset=\"https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/08\/CurrencyDice_M4DGROUP_Flickr.jpg 300w, https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/08\/CurrencyDice_M4DGROUP_Flickr-150x100.jpg 150w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><a href=\"http:\/\/www.missiontherapeutics.com\/\">Mission Therapeutics<\/a>, a research spin-off company from Cambridge University in the U.K., has raised \u00a36 million ($US 9.5 million) in Series A funding from a European venture capital syndicate. Series A investments represent the first round of significant funds raised after an enterprise&#8217;s initial launch.<\/p>\n<p>The company specializes in the discovery and development of drugs that translate research on DNA repair into therapies for life-threatening diseases like cancer. Mission Therapeutics was founded by <a href=\"http:\/\/www.gurdon.cam.ac.uk\/~jacksonlab\/steve_jackson.htm\">Steve Jackson<\/a>, a biology professor at Cambridge, and head of cancer research at the Gurdon Institute, Cambridge University.<\/p>\n<p>The Series A founding round is led by <a href=\"http:\/\/www.sofinnova.fr\/home-cl-en.html\">Sofinnova Partners<\/a>, an early-stage and spin-off venture capital company in Paris. The syndicate includes Imperial Innovations, SR One, and Roche Venture Fund. The investment marks Imperial Innovation&#8217;s <a href=\"http:\/\/www.imperialinnovations.co.uk\/node\/614\">first support<\/a> for a Cambridge spin-off company; it is the technology transfer arm of Imperial College London.<\/p>\n<p>Jackson and his co-founders &#8212; Niall Martin, Xavier Jacq, and Keith Menear &#8212; founded KuDOS Pharmaceuticals, a Cambridge-based biotech company, in 1997. KuDOS was acquired by the pharmaceutical company AstraZeneca in 2005.<\/p>\n<p>Read more: <a href=\"http:\/\/sciencebusiness.technewslit.com\/?p=5209\">Venture Company to Invest in Early-Stage Science Enterprises<\/a><\/p>\n<p>Photo: <a href=\"http:\/\/www.flickr.com\/photos\/m4dgroup\/6001102681\/in\/photostream\/\">MD4 Group\/Flickr<\/a><\/p>\n<p style=\"text-align: center;\">*\u00a0\u00a0\u00a0\u00a0 *\u00a0\u00a0\u00a0\u00a0 *<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mission Therapeutics, a research spin-off company from Cambridge University in the U.K., has raised \u00a36 million ($US 9.5 million) in Series A funding from a European venture capital syndicate. Series A investments represent the first round of significant funds raised after an enterprise&#8217;s initial launch. The company specializes in the discovery and development of drugs [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[31,21,51,74,23,45,64,27,90,26,19],"class_list":["post-5766","post","type-post","status-publish","format-standard","hentry","category-finance","tag-biomedical","tag-biotech","tag-cancer","tag-entrepreneurs","tag-equity","tag-europe","tag-life-sciences","tag-pharmaceuticals","tag-u-k","tag-university","tag-venture-capital"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/5766","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5766"}],"version-history":[{"count":3,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/5766\/revisions"}],"predecessor-version":[{"id":5770,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/5766\/revisions\/5770"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5766"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5766"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5766"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}